Welcome to CDC Stacks | Report from the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2-10 Years with Quadrivalent Meningococcal Conjugate Vaccine (MCV4) - 7428 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Report from the Advisory Committee on Immunization Practices (ACIP): Decision Not to Recommend Routine Vaccination of All Children Aged 2-10 Years with Quadrivalent Meningococcal Conjugate Vaccine (MCV4)
Filetype[HTML - ]
View this content


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
  • Keywords:
  • Description:
    At its February 2008 meeting, the Advisory Committee on Immunization Practices (ACIP) decided not to recommend routine vaccination of children aged 2--10 years against meningococcal disease unless the child is at increased risk for the disease. This report summarizes the deliberations of ACIP and the rationale for its decision and restates existing recommendations for meningococcal vaccination among children aged 2--10 years at increased risk for meningococcal disease. ACIP continues to recommend routine vaccination against meningococcal disease for all persons aged 11--18 years and those persons aged 2--55 years who are at increased risk for meningococcal disease (1--3).

  • Collection(s):
    Guidelines and Recommendations
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Revised recommendations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11-18 Years with Meningococcal Conjugate Vaccine.
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    August 10, 2007
    Source:
    MMWR. Morbidity and mortality weekly report. 2007; 56(31):794-5.
    Description:
    In January 2005, a quadrivalent meningococcal polysaccharide- protein conjugate vaccine (MCV4) (Menactra™, Sanofi Pasteur, Inc., Swiftwater, Pennsylvania) was licensed for use among persons aged 11–55 years. In May 2005, the Advisory Committee on...
    Status:
    superseded
    File Type:
    Filetype[PDF - 515.21 KB]
  2. Licensure of a Meningococcal Conjugate Vaccine for Children Aged 2 Through 10 Years and Updated Booster Dose Guidance for Adolescents and Other Persons at Increased Risk for Meningococcal Disease - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR 2011; 60 (30):1018-1019.
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    August 11, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(30):1018-9.
    Description:
    In January 2011, the Food and Drug Administration lowered the approval age range for use of MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics), a quadrivalent meningococcal conjugate vaccine, to include persons aged 2 through 55 years. One other...
    Status:
    superseded
    File Type:
    Filetype[PDF - 72.15 KB]
  3. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MenACWY-D) Among Children Aged 9 Through 23 Months at Increased Risk for Invasive Meningococcal Disease. MMWR 60 (40): 1391-1392.
    Corporate Author:
    United States. Advisory Committee on Immunization Practices.
    Published:
    October 14, 2011
    Source:
    MMWR. Morbidity and mortality weekly report. 2011; 60(40):1391-2.
    Description:
    In April 2011, the Food and Drug Administration approved the use of a quadrivalent meningococcal conjugate vaccine (MenACWY-D) (Menactra, Sanofi Pasteur) as a 2-dose primary series among children aged 9 through 23 months (1). Vaccination with meningo...
    Status:
    superseded
    File Type:
    Filetype[PDF - 64.63 KB]
  4. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated.
    Source:
    MMWR. Morbidity and mortality weekly report. 2008; 57(13):343-4.
    Description:
    This notice updates the recommendation for use of 7-valent pneumococcal conjugate vaccine (PCV7) among children aged 24-59 months who are either unvaccinated or who have a lapse in PCV7 administration. In February 2000, PCV7, marketed as Prevnar and ...
    Status:
    superseded
    File Type:
    Filetype[PDF - 319.43 KB]
  5. Quadrivalent human papillomavirus vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Chesson, Harrell W.; Dunne, Eileen F.; Lawson, Herschel W.; Markowitz, Lauri E.; Saraiya, Mona; Unger, Elizabeth R., 1951-;
    Corporate Author:
    National Center for HIV, STD, and TB Prevention (U.S.). Division of STD Prevention; Centers for Disease Control and Prevention (U.S.); United States. Advisory Committee on Immunization Practices;
    Published:
    March 23, 2007
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 56, no. RR-2
    Description:
    "These recommendations represent the first statement by the Advisory Committee on Immunization Practices (ACIP) on the use of a quadrivalent human papillomavirus (HPV) vaccine licensed by the U.S. Food and Drug Administration on June 8, 2006 [GA...
    Status:
    superseded
    File Type:
    Filetype[PDF - 444.25 KB]